Switching Between Biological Treatments in Psoriatic Arthritis: A Review of the Evidence

• Published in: Drugs in R&D 2017-12, Vol.17 (4), p.509-522
• Main Authors: Costa, Luisa, Perricone, Carlo, Chimenti, Maria Sole, Del Puente, Antonio, Caso, Paolo, Peluso, Rosario, Bottiglieri, Paolo, Scarpa, Raffaele, Caso, Francesco
• Format: Article
• Language: English
• Subjects: Arthritis; Internal Medicine; Medicine; Medicine & Public Health; Monoclonal antibodies; Pharmacology/Toxicology; Pharmacotherapy; Psoriatic arthritis; Review; Review Article; Tumor necrosis factor-TNF
• ISSN: 1174-5886; 1179-6901
• DOI: 10.1007/s40268-017-0215-7

Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy. Therapy with anti-tumor necrosis factor (TNF)-α agents represents the first therapeutic choice for moderate and severe forms; however, PsA patients can experience anti-TNFα failure, lack of efficacy, or adverse events. Several evidences exist on the effectiveness of switching among different TNFα inhibitors, and we reviewed the published data on the effectiveness of anti-TNFα first-, second- and third-line. Most of the studies report that the main reason for switching to a second anti-TNFα agent is represented by lack of efficacy (primary or secondary) and, more rarely, adverse events. Switchers receiving their second anti-TNFα agent have considerably poorer responses compared with non-switchers. Survival of anti-TNFα treatment appears to be superior in PsA patients when compared with rheumatoid arthritis patients. Switching from anti-TNF agents to ustekinumab or secukinumab or apremilast can represent a valid alternative therapeutic strategy.